Abbott Secures FDA Approval for Ultreon 3.0 Imaging Platform

FDA Clears Abbott’s AI-Powered Coronary Imaging Software

The Ultreon 3.0 software uses optical coherence tomography and artificial intelligence to guide physicians during procedures to open blocked arteries. Abbott has received US Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon 3.0 Software, an artificial intelligence (AI) powered imaging platform. According to the company, the system integrates coronary imaging with AI-automated insights to support physicians …

Abbott’s latest-generation Ultreon software gains FDA approval, CE mark

Abbott has received US Food and Drug Administration (FDA) clearance and CE marking for its next-generation Ultreon 3.0 software. Ultreon 3.0 is an artificial intelligence (AI)-powered imaging platform that uses optical coherence tomography (OCT) to give doctors real-time planning guidance while they perform percutaneous coronary intervention (PCI), incorporating AI to assess the type of plaque causing the blockage “Ultreon 3.0 represents a pivot…

Abbott secures FDA approval for Ultreon 3.0 imaging platform

Abbott has received the US FDA approval and CE Mark for its Ultreon 3.0 artificial intelligence (AI)-powered coronary imaging platform.The post Abbott secures FDA approval for Ultreon 3.0 imaging platform appeared first on Medical Device Network.

Abbott gains FDA clearance, CE mark approval for AI-powered imaging platform

Ultreon 3.0 was built to capture and evaluate OCT images, providing real-time guidance during complex PCI procedures.